Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology

European Journal of Cancer

Volumn 50, Issue 17, 2014, Pages 2916-2924

  Karlsson, E ^a,b   Appelgren, J ^c   Solterbeck, A ^b   Bergenheim, M ^b   Alvariza, V ^b   Bergh, J ^a  

^a University Hospital   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KARLSTAD UNIVERSITY   (Sweden)

Author keywords

Biomarker; Human epidermal growth factor receptor 2; Keywords Breast cancer; Oestrogen receptor; Progesterone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRECANCER AND CANCER-IN-SITU; PRIORITY JOURNAL; SKIN CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VULVA CANCER; VULVAL INTRAEPITHELIAL NEOPLASIA; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; EPIDEMIOLOGY; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDY; SECOND CANCER; SWEDEN;

ADULT; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84922480878     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.08.014     Document Type: Article

References (32)

1. N. Niikura, J. Liu, N. Hayashi, E.A. Mittendorf, Y. Gong, and S.L. Palla Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 6 2012 593 599 Epub 2011/11/30
2. A.M. Thompson, L.B. Jordan, P. Quinlan, E. Anderson, A. Skene, and J.A. Dewar Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) Breast Cancer Res 12 6 2010 R92 Epub 2010/11/10
3. L.S. Lindstrom, E. Karlsson, U.M. Wilking, U. Johansson, J. Hartman, and E.K. Lidbrink Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 21 2012 2601 2608 Epub 2012/06/20
4. E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, and C. Simmons Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 6 2012 587 592 Epub 2011/11/30
5. T. Foukakis, G. Astrom, L. Lindstrom, T. Hatschek, and J. Bergh When to order a biopsy to characterise a metastatic relapse in breast cancer Ann Oncol 23 suppl. 10 2012 x349 53 Epub 2012/09/26
6. L. Lindström, S. Howell, G. Åström, U. Wilking, E. Lidbrink, and A. Armstrong Controversies in the management of metastatic breast cancer: biologic evaluation of breast cancer - should metastases be biopsied? Chicago 2010 American Society of Clinical Oncology Illionois
7. G. Aurilio, D. Disalvatore, G. Pruneri, V. Bagnardi, G. Viale, and G. Curigliano A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases Eur J Cancer 2013 Epub 2013/11/26
8. U. Wilking, E. Karlsson, L. Skoog, T. Hatschek, E. Lidbrink, and G. Elmberger HER2 status in a population-derived breast cancer cohort: discordances during tumor progression Breast Cancer Res Treat 125 2 2011 553 561 Epub 2010/07/16
9. C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S.W. Kau, and W.F. Symmans Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 12 2009 1953 1958 Epub 2009/07/15
10. C. Simmons, N. Miller, W. Geddie, D. Gianfelice, M. Oldfield, and G. Dranitsaris Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 9 2009 1499 1504 Epub 2009/03/21
11. S. van de Ven, V.T. Smit, T.J. Dekker, J.W. Nortier, and J.R. Kroep Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer Cancer Treat Rev 37 6 2011 422 430 Epub 2010/12/24
12. G. von Minckwitz, S. Darb-Esfahani, S. Loibl, J. Huober, H. Tesch, and C. Solbach Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer - results from the GeparQuattro study (GBG 40) Breast Cancer Res Treat 132 3 2012 863 870 Epub 2011/06/15
13. R. Duchnowska, R. Dziadziuszko, T. Trojanowski, T. Mandat, W. Och, and B. Czartoryska-Arlukowicz Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain Breast Cancer Res 14 4 2012 R119 Epub 2012/08/18
14. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 1687 1717 Epub 2005/05/17
15. T. Kuukasjarvi, J. Kononen, H. Helin, K. Holli, and J. Isola Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 9 1996 2584 2589 Epub 1996/09/01
16. M. Colleoni, Z. Sun, G. Martinelli, R.L. Basser, A.S. Coates, and R.D. Gelber The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up Ann Oncol 20 8 2009 1344 1351 Epub 2009/05/27
17. E. de Azambuja, F. Cardoso, G. de Castro Jr.; M. Colozza, M.S. Mano, and V. Durbecq Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 10 2007 1504 1513 Epub 2007/04/25
18. Nielsen T, Polley M-Y, Leung S, Mastropasqua M, Zabagio L, Bartlett J, et al. An International Ki67 reproducibility study. San Antonio Breast Cancer Symposium; 15 December; San Antonio: Cancer Research; 2012.
19. E. Luporsi, F. Andre, F. Spyratos, P.M. Martin, J. Jacquemier, and F. Penault-Llorca Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review Breast Cancer Res Treat 132 3 2012 895 915 Epub 2011/11/04
20. L. Pusztai, G. Viale, C.M. Kelly, and C.A. Hudis Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 11 2010 1164 1168 Epub 2010/11/03
21. M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I.E. Smith, and M. Dowsett Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 12 2009 1948 1952 Epub 2009/07/03
22. G. Aurilio, L. Monfardini, S. Rizzo, A. Sciandivasci, L. Preda, and V. Bagnardi Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer Acta Oncol 52 8 2013 1649 1656 Epub 2013/01/19
23. I.J. Fidler, and M.L. Kripke Metastasis results from preexisting variant cells within a malignant tumor Science 197 4306 1977 893 895 Epub 1977/08/26
24. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892 Epub 2012/03/09
25. A.E. Karnoub, A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, and G.W. Bell Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 7162 2007 557 563 Epub 2007/10/05
26. G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, and H. Zhao Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 5 2008 518 527 Epub 2008/04/29
27. L. Ding, M.J. Ellis, S. Li, D.E. Larson, K. Chen, and J.W. Wallis Genome remodelling in a basal-like breast cancer metastasis and xenograft Nature 464 7291 2010 999 1005 Epub 2010/04/16
28. T. Norberg, S. Klaar, G. Karf, H. Nordgren, L. Holmberg, and J. Bergh Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort Cancer Res 61 22 2001 8317 8321 Epub 2001/11/24
29. N. Navin, J. Kendall, J. Troge, P. Andrews, L. Rodgers, and J. McIndoo Tumour evolution inferred by single-cell sequencing Nature 472 7341 2011 90 94 Epub 2011/03/15
30. R.J. Gillies, D. Verduzco, and R.A. Gatenby Evolutionary dynamics of carcinogenesis and why targeted therapy does not work Nat Rev Cancer 12 7 2012 487 493 Epub 2012/06/15
31. L. Mellemkjaer, S. Friis, J.H. Olsen, G. Scelo, K. Hemminki, and E. Tracey Risk of second cancer among women with breast cancer Int J Cancer 118 9 2006 2285 2292 Epub 2005/12/13
32. L.B. Travis, C.S. Rabkin, L.M. Brown, J.M. Allan, B.P. Alter, and C.B. Ambrosone Cancer survivorship - genetic susceptibility and second primary cancers: research strategies and recommendations J Natl Cancer Inst 98 1 2006 15 25 Epub 2006/01/05